SBC Medical Group (SBC) Furnishes Q2 2025 Results, Presentation

SBC Medical Group Holdings Incorporated furnished a press release and an investor presentation reporting results for the quarter ended June 30, 2025.

Rhea-AI Filing Summary

SBC Medical Group Holdings Incorporated furnished a press release and an investor presentation reporting results for the quarter ended June 30, 2025. The press release is included as Exhibit 99.1 and the investor presentation as Exhibit 99.2, with the presentation available on the company website at https://sbc-holdings.com/en/ir/ir-presentation. The report specifies these items are furnished, not filed under the Exchange Act and therefore are not subject to Section 18 liabilities. The company identifies as an emerging growth company and lists its common stock (SBC) and redeemable warrants (SBCWW) on The Nasdaq Stock Market LLC.

Insights

Financial Analyst

TL;DR The 8-K furnishes Q2 materials but contains no financial data in the filing itself, so investor impact is limited.

As provided, the filing supplies a press release and investor presentation for the quarter ended June 30, 2025, attached as Exhibits 99.1 and 99.2. The company explicitly states these materials are furnished rather than filed under the Exchange Act, which limits legal liability under Section 18. From the document alone there are no results or metrics to evaluate, so the filing functions as routine disclosure of investor materials rather than a material event.

Impact assessment: not impactful

Corporate Governance Expert

TL;DR Routine disclosure of investor communications; governance implications minimal based on this filing alone.

The current report documents that a press release and an investor presentation concerning the quarter ended June 30, 2025 were furnished and tied to Exhibits 99.1 and 99.2. The filing also indicates the registrant is an emerging growth company and confirms securities trading symbols (SBC and SBCWW) on Nasdaq. Because the materials are furnished and not filed, the registrant limits incorporation and Section 18 exposure. No governance actions, officer changes, or material transactions are disclosed in this report.

Impact assessment: not impactful

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did SBC (SBC) disclose in this 8-K?

The company furnished a press release and an investor presentation reporting results for the quarter ended June 30, 2025, attached as Exhibits 99.1 and 99.2.

Are the press release and presentation filed with the SEC?

No. The filing states these items are furnished, not filed, under the Exchange Act and are not subject to Section 18 liabilities.

Where can investors find the investor presentation for SBC?

The presentation is posted on the company website at https://sbc-holdings.com/en/ir/ir-presentation and is attached as Exhibit 99.2 to the 8-K.

What securities of SBC are registered for trading?

Common Stock (SBC) and Redeemable Warrants (SBCWW) are registered and trade on The Nasdaq Stock Market LLC.

Does the 8-K indicate any executive changes or major transactions?

No. The report only furnishes investor materials and does not disclose leadership changes or material transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/13/2025 - 07:00 AM Learn about SEC filing dates

false 0001930313 0001930313 2025-08-13 2025-08-13 0001930313 SBC:CommonStock0.0001ParValuePerShareMember 2025-08-13 2025-08-13 0001930313 SBC:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50PerShareMember 2025-08-13 2025-08-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 13, 2025

SBC Medical Group Holdings Incorporated

(Exact name of registrant as specified in its charter)

Delaware		001-41462		88-1192288
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

200 Spectrum Center Dr. STE 300 Irvine, CA		92618
(Address of principal executive offices)		(Zip Code)

949-593-0250

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		SBC		The Nasdaq Stock Market LLC
Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 per share		SBCWW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On August 13, 2025, SBC Medical Group Holdings Incorporated (the “Company”), issued a press release announcing its results for the quarter ended June 30, 2025. The press release is attached as Exhibit 99.1 and is incorporated herein by reference.

Additionally, on August 13, 2025, the Company posted an investor presentation to its website (https://sbc-holdings.com/en/ir/ir-presentation ), regarding results for the quarter ended June 30, 2025 which presentation is attached hereto as Exhibit 99.2 and incorporated by reference herein.

The information furnished under Item 2.02, including Exhibit 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated by specific reference in any such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated August 13, 2025, entitled “SBC Medical Group Holdings Announces Second Quarter 2025 Financial Results”
99.2		Investor Presentation
101		Pursuant to Rule 406 of Regulation S-T, the cover page to this Current Report on Form 8-K is formatted in Inline XBRL.
104		Cover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit 101).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

	SBC Medical Group Holdings Incorporated
Dated: August 13, 2025	By:	/s/ Yuya Yoshida
		Yuya Yoshida
		Chief Financial Officer